ArticleBMC infectious diseases2026
Preliminary assessment of the use of targeted next-generation sequencing technology for detecting lymph node tuberculosis using ultrasound-guided core needle biopsy specimens.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThe current study aimed to evaluate the diagnostic utility of targeted next-generation sequencing (tNGS) technology in detecting lymph node tuberculosis (LNTB) using ultrasound-guided puncture core needle biopsy (CNB) samples.
methodsThis study was conducted on patients who underwent ultrasound-guided CNB operation. The samples obtained were used for the tNGS assay, mycobacterial tuberculosis (MTB) culture, Xpert MTB/RIF assay, and pathological examination. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) of these assays were calculated. Then, their diagnostic efficacy was compared with that of the composite reference standard.
resultsThe sensitivity, specificity, PPV, NPV, and AUC of the tNGS assay for detecting LNTB were 95.4%, 88.9%, 98.4%, 72.7%, and 0.921, respectively. Those of the MTB culture were 26.2%, 100.0%, 100.0%, 15.8%, and 0.631, respectively. Those of the Xpert MTB/RIF assay were 72.3%, 100.0%, 100.0%, 33.3%, and 0.862, respectively. Those of the pathological examination were 80.0%, 88.9%, 98.1%, 38.1%, and 0.844, respectively. Among the tests, the tNGS assay had the highest sensitivity, and the results significantly differed among the methods.
conclusionThe tNGS assay using CNB samples had a superior diagnostic efficacy for diagnosing LNTB. Hence, it has potential in clinical application. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.